The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: The paradox study

Journal of the American College of Cardiology

Volumn 62, Issue 6, 2013, Pages 505-512

  Gurbel, Paul A ^a   Bliden, Kevin P ^a   Logan, Douglas K ^b   Kereiakes, Dean J ^c   Lasseter, Kenneth C ^d   White, Alex ^e   Angiolillo, Dominick J ^f   Nolin, Thomas D ^g   Maa, Jen Fue ^h   Bailey, William L ^h   Jakubowski, Joseph A ⁱ   Ojeh, Clement K ⁱ   Jeong, Young Hoon ^a   Tantry, Udaya S ^a   Baker, Brian A ^h  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b Medpace Clinical Pharmacology ^*  (United States)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d Clinical Pharmacology of Miami Inc   (United States)

^e Progressive Medical Research   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h DAIICHI SANKYO INC   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

clopidogrel; CYP1A2; CYP2C19; pharmacodynamics; pharmacokinetics; platelet; prasugrel; smoking

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; COTININE; CYTOCHROME P450 1A2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANIC NITRATE; PHOSPHOPROTEIN; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; VASODILATOR AGENT;

ADULT; AGED; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; CYP2C19 GENE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; GENE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PILOT STUDY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SMOKING HABIT; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE LEVEL;

ACTIVE METABOLITE; AM; AREA UNDER THE CURVE; AUC; C-IPA; CAD; CALCULATED INHIBITION OF PLATELET AGGREGATION; CI; CLOPIDOGREL; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; CYP; CYP1A2; CYP2C19; CYTOCHROME; DEVICE-REPORTED INHIBITION OF PLATELET AGGREGATION; DR-IPA; EM; EXTENSIVE METABOLIZERS; HIGH ON-TREATMENT PLATELET REACTIVITY; HPR; LEAST SQUARES; LS; ODDS RATIO ESTIMATES; ORE; P2Y(12) REACTION UNITS; PD; PHARMACODYNAMICS; PHARMACOKINETICS; PK; PLATELET; PLATELET REACTIVITY INDEX; PRASUGREL; PRI; PRU; REDUCED METABOLIZER; RM; SMOKING; VASODILATOR-STIMULATED PHOSPHOPROTEIN PHOSPHORYLATION; VASP;

AGED; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SMOKING; THIOPHENES; TICLOPIDINE;

EID: 84881112989     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.03.037     Document Type: Article

References (18)

1. P.A. Gurbel, and U.S. Tantry Combination antithrombotic therapies Circulation 121 2010 569 583
2. P.A. Gurbel, T.D. Nolin, and U.S. Tantry Clopidogrel efficacy and cigarette smoking status JAMA 307 2012 2495 2496
3. K.P. Bliden, B.A. Baker, and T.D. Nolin Thienopyridine efficacy and cigarette smoking status Am Heart J 165 2013 693 703
4. K.P. Bliden, J. Dichiara, and L. Lawal The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 52 2008 531 533
5. M. Ueno, J.L. Ferreiro, and B. Desai Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study J Am Coll Cardiol Intv 5 2012 293 300
6. A.M. Yousef, T. Arafat, and N.R. Bulatova Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel J Clin Pharm Ther 33 2008 439 449
7. P.A. Gurbel, and U.S. Tantry Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents Circulation 125 2012 1276 1287
8. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy Am Heart J 161 2011 598 604
9. P.A. Gurbel, K.P. Bliden, and W. Samara Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study J Am Coll Cardiol 46 2005 1827 1832
10. N.A. Farid, M. McIntosh, and F. Garofolo Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/ tandem mass spectrometry Rapid Commun Mass Spectrom 21 2007 169 179
11. M. Takahashi, H. Pang, and K. Kawabata Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS J Pharm Biomed Anal 48 2008 1219 1224
12. U. Fuhr, and K.L. Rost Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva Pharmacogenetics 4 1994 109 116
13. W. Hochholzer, D. Trenk, and J.L. Mega Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy Am Heart J 162 2011 518 526.e5
14. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
15. S.S. Brar, J. ten Berg, and R. Marcucci Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 2011 1945 1954
16. F. Mangiacapra, G. Patti, and A. Peace Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention Am J Cardiol 106 2010 619 623
17. C.D. Payne, Y.G. Li, and D.S. Small Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel J Cardiovasc Pharmacol 50 2007 555 562
18. I. Washio, M. Maeda, and C. Sugiura Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes Drug Metab Dispos 39 2011 1 3.